~~<i id='ED1AAFE75D'><strike id='ED1AAFE75D'><tt id='ED1AAFE75D'><pre id='ED1AAFE75D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：knowledge 2025-09-05 13:43:30 - browse：3

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Physicians aren't 'burning out.' They're suffering from moral injury

entertainment

hotspot

focus

Wikipedia

focus

AdobeLauraBrownknowsthatshehashighcholesterol,andthatassomeonewholiveswithbipolar1disorder,shefacese

WSS

FDA approves Sage Therapeutics’ rapid

Medicare slashes safety net hospital payments by nearly $1 billion

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

The problems with dementia villages

Pharma showers House GOP doctor with campaign cash

FDA scientists endorse Pfizer/BioNTech Covid

leisure time

entertainment

entertainment

Hollywood unions extend contract negotiations for actors

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cassava Sciences’ Alzheimer’s clinical trials should be halted

After affirmative action ruling, medical educators look to 'holistic review'

When waiting feels immoral: Empathy in the emergency department

Trump demands the U.S. pay no more for drugs than other countries … again

Why a market frenzy over new weight loss drugs defies logic

Trump demands the U.S. pay no more for drugs than other countries … again

Is there really a nursing shortage in the U.S.?

hotspot

Study on Amgen’s bispecific immunotherapy produces positive data

Flint parents haunted by uncertainty, fears of lead poisoning

The problems with dementia villages

STAT Readout: Friday, Oct. 20 biotech updates

UnitedHealth, Optum discontinue NaviHealth name

STAT Summit: How researchers deal with rejection

focus

Wikipedia

focus

focus